Can someone point me to some research that discusses EEP's forward looking prospects for sales and its dividend? Opinions? I am concerned that EEP's customers get squeezed by Middle East oil turning up volume. I can wait out the low stock price if I get a good feeling about the dividend.
I sense we could be looking at a really good opportunity but I can't quite pull the trigger.
Zetia is currently a $3 billion drug from MRK. It treats LDL cholesterol for those that are statin intolerant, and is combined with statins. It's a pill. ETC-1002 has shown to be more effective than Zetia both as a stand alone therapy or when taken with a statin. Also, when combining Zetia and ETC-1002, patients see a 48% reduction in LDL. All oral.
If Zetia is a $ 3 billion drug, what is ETC-1002?
Complicating matters are the REGN and AMGN drugs (needles) that will hit market later this year.
If the street starts to believe this is a multi-billion drug, how long do you think this will stay down?
Fair points. This could happen. Based n my research, this would be a huge buying opportunity and it will not stay down too long.
Maybe. Or maybe it's up $20 tomorrow. Or maybe it's taken out in a week. MRK's Zetia does $3-$4 billion or so in annual sales. ETC-1002 beats in it on every metric.
Zetia and ETC-1002, when combined, achieve almost 50% reduction in LDL. It would capture all of the statin intolerant market, and beat out REGN and AMGN drugs because all oral. Plus ETC-1002 superior to Zetia as an additive to statins.
They can combine Zetia with ETC-1002 and the combo reduces cholesterol almost as much as a statin - with less side effects. Othewise they will be forced to compete with ETC-1002, and ETC-1002 looks like the winner.
What is this drug's potential market? REGN and AMGN drugs supposedly $10 billion. This will be priced cheaper and probably only get a slice. So what is the annual sales target here?
4? I was only aware of possibly 3. Can you list? Thanks. Also, your previous post would be helpful if there was a link to the report you cited.